Earnings call transcript: Applied DNA Sciences Q1 FY25 revenue grows
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals multiple red flags: substantial going concern doubts, high cash burn, competitive pressures, and regulatory compliance challenges. Despite revenue growth and cost management improvements, the financial health remains precarious. The Q&A section highlights unclear management responses, especially regarding revenue opportunities. The workforce reduction charge and increased net loss further amplify concerns. These factors suggest a negative outlook, with potential stock decline due to financial instability and operational uncertainties.
Key Financial Performance
Total Revenues $1,200,000 (up from $891,000), a year-over-year increase due to higher product revenues from the DNA tagging business and an increase in textiles isotopic testing services revenue.
Operating Loss $3,000,000 (improved from $3,800,000), primarily due to lower selling, general and administrative costs related to reduced stock-based compensation and decreased consulting expenses from the closure of the DNA tagging segment's European subsidiary.
Net Loss $2,700,000 (compared to $1,100,000), with the increase attributed to an unrealized gain on the change in the fair value of warrants classified as a liability.
Adjusted EBITDA Negative $2,900,000 (improved from negative $3,200,000), indicating a reduction in losses year-over-year.
Cash and Cash Equivalents $9,300,000 (up from $6,400,000), reflecting net proceeds of approximately $5,700,000 from the October offering and Series A warrant exercises.
Average Monthly Cash Burn Just over $1,200,000, essentially flat compared to the same period in the prior year.
Cash and Cash Equivalents (as of January 31, 2025) $8,200,000, which includes additional Series A warrant exercises totaling approximately $215,000.
One-time Charge Approximately $300,000 related to workforce reduction due to the exit from the DNA Tagging and Security Products and Services business segment.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launch: Introduced Linea Donor DNA for CRISPR gene editing applications, optimized for high fidelity and double-stranded DNA. Launched TraitPGX, a pharmacogenomics assay, approved by New York State Department of Health.
Market Expansion: Secured GMP certification for Site 1, enabling entry into long-term GMP supplier agreements. Expanded mPOXX assay usage to accept samples from all 50 states.
Operational Efficiency: Implemented a strategic restructuring to reduce cash burn rate and optimize cost structure. Achieved a reduction in operating loss from $3.8 million to $3 million year-over-year.
Strategic Shift: Exited the DNA Tagging and Security Products and Services business segment, anticipating completion by the end of the current quarter. Promoted Judy Murrah to President to oversee operational excellence and growth initiatives.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Strategic Restructuring: The company initiated a strategic restructuring to bolster cash reserves and optimize cost structure, which included a workforce reduction of approximately 20% and a one-time charge of $300,000.
Exit from DNA Tagging Segment: The company announced its exit from the DNA Tagging and Security Products and Services business segment, which may impact revenue and customer relationships.
Going Concern: There is a substantial doubt regarding the company's ability to continue as a going concern, dependent on its ability to implement its business plan and generate revenues or raise capital.
Cash Burn Rate: The average monthly cash burn is over $1,200,000, which poses a risk to financial stability if not managed effectively.
Regulatory Compliance: The company must adhere to stringent regulatory requirements from the FDA and other authorities, which can impact operational flexibility and costs.
Market Competition: The company faces competitive pressures in the biotherapeutics market, particularly in enzymatic DNA production, which could affect market share and pricing.
Customer Acquisition and Retention: The success of the company's growth strategy relies on acquiring and retaining customers in a competitive landscape, which poses a risk if not achieved.
Operational Execution: The operational launch of the GMP facility is critical; failure to execute effectively could hinder growth and profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Restructuring: Initiated to bolster cash reserves and optimize cost structure, reducing cash burn rate and supporting growth of synthetic DNA manufacturing via LinearRx.
Exit from DNA Tagging and Security Products: Announced exit from this business segment, with wind down expected to be completed by the end of the current quarter.
Workforce Reduction: Implemented a 20% workforce reduction related primarily to the DNA tagging segment.
GMP Certification: Certification of GMP Site 1 facility, enabling the company to deliver products ranging from evaluation to clinical grade.
New Product Development: Developing new forms of Linea DNA, including Linea Donor DNA for CRISPR applications.
Revenue Expectations: Initial revenue opportunity for LineaRx for IVT templates ranges from $50,000 to $1,000,000 per opportunity.
Projected Annual Capacity: Initial projected annual IVT template capacity of over 10 grams, sufficient for producing up to 30,000,000 doses of mRNA vaccines.
CapEx Requirements: Each modular cleanroom costs less than $1,000,000 with potential revenue opportunities of $10,000,000 to $30,000,000 per year.
Market Demand: Strong market demand for Linea DNA and Linea IVT platforms, with over 25 active projects in fiscal 2024.
Future Growth Strategy: Focus on leveraging low CapEx requirements to achieve growth and profitability.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Workforce Reduction Charge: A one-time charge of approximately $300,000 will be incurred in the quarter ending March 31 related to the workforce reduction of approximately 20% of total headcount.
Cash and Cash Equivalents: As of December 31, cash and cash equivalents totaled $9,300,000, which includes net proceeds of approximately $5,700,000 from the October offering.
Average Monthly Cash Burn: The average monthly cash burn is just over $1,200,000 fiscal year to date.
Projected Annual IVT Template Capacity: The initial projected annual IVT template capacity is over 10 grams, sufficient for producing up to 30,000,000 doses of mRNA vaccines.
Revenue Opportunity for IVT Templates: The initial revenue opportunity for LineaRx for IVT templates ranges from about $50,000 to $1,000,000 per opportunity.
Revenue Opportunity for IVT Templates with Linea RNApp: The revenue opportunity for IVT templates sold with corresponding Linea RNApp ranges from about $150,000 to $3,000,000 per opportunity.
GMP Facility Cost: Each modular cleanroom costs less than $1,000,000, with a potential revenue opportunity of $10,000,000 to $30,000,000 per year.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide any color on the new Linea products and how you quantify the opportunity for CRISPR therapies versus conventional IVT or existing CAR T therapies?
A:We think that there's a lot of parallels between the IVT template and the donor DNA market. We believe it is a very large market, especially in cell and gene therapy as CAR Ts start to move more to the gene editing space.
Q:Where are the revenue increases coming from? Are they primarily new customer acquisitions or from increased scaling and manufacturing of existing customers?
A:The increases came from product revenue, primarily from a shipment of DNA tagging for marking cotton and increased volumes in our isotopic testing services business.
Q:What is the timeline and revenue recognition dynamics for the AML therapy mentioned?
A:The timeline for the trial is about eighteen months. We don't know the revenue opportunity as it's a hospital-based trial, but it was important for regulatory validation.
Q:Review of Unclear Management Responses
A:Management did not provide a clear answer regarding the potential revenue opportunity from the AML therapy trial, stating it was a hospital-based trial and not run by a commercial entity, which left the revenue potential vague.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CAR
CEO Applied
Chairman CEO
DNA manufacturing
DNA market
DNA production
DNA use
GMP facility
GMV
ISO
IVT template
LRx
LinearX Applied
Officer President
Phase
President LinearX
Rx
Sharrock Chief
addition
cost
donor DNA
focus
gene editing
grade
instrument
instrumentation
investment
kind
market opportunity
month
opportunity template
path
profitability
project
quality
restructuring
role
site
space
structure
subsidiary
trial
APDN Transcript
Earnings call transcript: Applied DNA Sciences Q1 FY25 revenue grows
Unknown2-13
The earnings call reveals multiple red flags: substantial going concern doubts, high cash burn, competitive pressures, and regulatory compliance challenges. Despite revenue growth and cost management improvements, the financial health remains precarious. The Q&A section highlights unclear management responses, especially regarding revenue opportunities. The workforce reduction charge and increased net loss further amplify concerns. These factors suggest a negative outlook, with potential stock decline due to financial instability and operational uncertainties.
Applied DNA Sciences, Inc. (APDN) Q3 2024 Earnings Call Transcript
Unknown8-11
The earnings call summary highlights several concerns: substantial revenue decline, increased cash burn rate, and doubts about the company's ability to continue as a going concern. Regulatory delays and competitive pressures further exacerbate these issues. The Q&A section reveals management's lack of clarity on future customer uptake and test volumes, adding to uncertainties. Despite the potential for additional proceeds from warrant exercises, the overall sentiment is negative due to financial struggles, market competition, and regulatory hurdles. The stock is likely to experience a negative movement of -2% to -8% over the next two weeks.
Applied DNA Sciences, Inc. (APDN) Q1 2024 Earnings Call Transcript
Unknown2-9
The earnings call revealed a significant decline in total revenue, gross profit, and cash reserves, along with increased operating expenses and losses. While there were some service revenue gains, they were insufficient to offset the overall financial deterioration. The Q&A highlighted ongoing developments and potential in the CD123 CAR therapy and Linea IVT platform, but lacked detailed guidance or significant positive catalysts. The financial challenges and lack of clear guidance suggest a negative sentiment, likely leading to a stock price decrease in the next two weeks.
Applied DNA Sciences, Inc. (APDN) Q4 2023 Earnings Call Transcript
Unknown12-8
The earnings call highlights several concerns: declining revenue, reduced gross margin, and flat operating loss and EBITDA. The cash position decreased significantly, indicating financial strain. Although there are promising developments in product adaptation and potential growth in the Linea IVT platform, management's vague responses about timelines and revenue projections add uncertainty. The positive aspects, such as the IND approval and potential revenue growth from new platforms, are overshadowed by the immediate financial challenges and unclear guidance, leading to a negative sentiment.
APDN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
